Microbiotica

Microbiotica is a clinical-stage biopharmaceutical company focused on developing precision live biotherapeutic products (LBPs) derived from the human microbiome. Founded in 2016 as a spin-out from the Wellcome Sanger Institute, the company is based in Cambridge, UK, and has successfully raised £62 million in equity investment, including a significant £50 million Series B funding round in 2022. The company utilizes a proprietary microbiome profiling platform that includes a diverse culture collection of bacterial strains, a reference genome database, and advanced bioinformatics tools. This platform supports a clinic-led discovery approach, allowing Microbiotica to identify specific bacterial strains linked to positive health outcomes. Their lead candidates include MB097, aimed at enhancing immune checkpoint inhibitors for melanoma, and MB310, targeting ulcerative colitis. Microbiotica is also exploring additional therapeutic candidates across various disease areas, including inflammatory bowel disease and immuno-oncology. The company has partnered with Genentech to analyze patient samples and develop new therapeutic products.